clinical trial · NCT05232071
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
Inventiva Pharma·phase2·completed·n = 39
NASH - Nonalcoholic SteatohepatitisDiabetes Mellitus, Type 2LanifibranorPlaceboEmpagliflozin
brief summary
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
started
Jun 29, 2022
primary completion
May 8, 2024
completion
Jun 4, 2024
last updated
Sep 9, 2026
official title
A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol